Navigation Links
Building bridges between the clinic and the laboratory
Date:8/4/2008

Cambridge, UK, 04 August 2008 - Disease Models & Mechanisms (DMM) is the first journal to focus on translational research and the use of model organisms to advance human health. Published by the Company of Biologists, DMM is a highly anticipated biomedical research journal which officially launched its inaugural issue both in print and online today at http://DMM.biologists.org.

DMM focuses on human disease and the research necessary to develop treatments for illness. The field of translational medicine where basic science research is "translated" into treatments and cures for disease has been growing exponentially, particularly given the recent advances in genomics and life sciences, and shifts in global research funding. DMM aims to fill a niche in translational research by publishing articles about human disease and the model organisms used in biomedical research.

The special inaugural issue features editorial commentary, review articles, and research highlights on topics ranging from cancer detection, to understanding human diseases using flies or worms and the future impact of mouse genetics on humankind. Future issues will include primary research articles, and DMM continues to invite authors to submit articles which focus on human disease. Interviews and Podcasts focusing on areas of special interest will become regular features.

DMM's founders believe that the journal will provide a community forum for clinicians and scientists to discuss their findings and observations. DMM's Editor-in-Chief, Vivian Siegel, invites students, fellows, policymakers, clinicians, and scientists to "use the journal and its website to share resources and discoveries".

In addition to its publishing goals, the journal is committed to assisting early-career scientists by offering travelling fellowships to graduate students and postdoctoral fellows. Awards of up to US$5000/₤2500 are offered to facilitate collaborative visits to other laboratories worldwide. Fellowship application forms can be downloaded from the DMM website.

Disease Models & Mechanisms will publish 5 issues in 2008. Issue 1 is a special inaugural issue; issues 2/3 and 4/5 will be combined double issues. From 2009, DMM will be published every month (12 issues/year). Authors benefit from a free trial period for access to DMM, which will be available until at least spring 2009. DMM is a new addition to the international journals published by the Company of Biologists, a not-for-profit publisher based in Cambridge, UK.


'/>"/>

Contact: Donna Perry
donna@biologists.com
44-122-342-6164
The Company of Biologists
Source:Eurekalert

Related biology news :

1. 1/3 of reef-building corals face extinction
2. NJIT architect professor advocates best-building practices for high wind regions
3. Manchester clears first hurdle in €170 million biobank building boom
4. Building on pyramids of trash
5. UCI awarded $27.2 million for new stem cell building
6. Scientists make chemical cousin of DNA for use as new nanotechnology building block
7. In Todays Economy, You Can Strengthen Your Company by Building Your Brand
8. International workshop to address capacity building for rainforest leaders
9. Building the future -- 21st century nano tools to repair the nervous system
10. Building disease-beating wheat
11. Building blocks of life formed on Mars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud with ... Reading ... Used combined in one project, multi-biometric solutions provide a crucial ... Used combined in ... ...
(Date:3/7/2017)...   HireVue , the leading provider of video ... best talent, faster, today announced the additions of ... Diana Kucer as Chief Marketing Officer (CMO). ... poised to drive continued growth in the company,s new ... record bookings in 2017. "Companies worldwide turn ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... Denmark , March 22, 2017  Ascendis ... utilizes its innovative TransCon technology to address significant ... financial results for the full year ended December ... significant year for our company as we broadened ... a leading, integrated rare disease company with an ...
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com ... ... cancer conditions are being pressured as of late due to ... cancer pain management has a dramatic impact on patient,s quality ... and development activities for identifying new forms of opioid formulations ...
(Date:3/22/2017)... 22, 2017   VWR (NASDAQ: ... product and service solutions to laboratory and ... acquired EPL Archives, Inc., an international biorepository ... entire regulated product research, development and commercialization ... and ancillary services. EPL Archives is widely ...
Breaking Biology Technology: